The scientific goal of the Hollings Cancer Center (HCC) Developmental Cancer Therapeutics (DCT) Program is to discover and characterize unique agents and pathways that will impact the development of more effective cancer therapies and to translate these discoveries into clinical applications by using proof-of principle, early phase clinical and correlative science studies. The DCT Program is co-led by Kenneth D. Tew, PhD and Carolyn D. Britten, MD. The DCT Program is organized around three themes of scientific investigation: ? Elucidation of Cellular Signaling Pathways. ? Modulation of Redox and Cellular Stress Response. ? Development of Small Molecule Chemotherapeutic Agents. The 46 members of the DCT Program, representing 12 departments within the College of Medicine and the College of Pharmacy, have 87 active grants/contracts totaling $11.7M in cancer research funding ($7.7 in peer-reviewed funding and $3.7M from the NCI). In 2012 the DCT Program implemented 65 early phase (pilot. Phase I, Phase l/ll, and Phase II) interventional treatment clinical trials, of which 25 were invesfigator initiated;224 patients were enrolled onto all DCT Program interventional treatment studies. In the past five years, DCT Program members produced 305 cancer-focused publications with 17% of these representing inter-programmatic and 35% intra-programmatic collaborations and 48% from mulfi-insfitutional collaborations.
Members of the Developmental Cancer Therapeutics Program are linked by synergistic research interests with a focus on drug discovery and development. Collaborations between this program's clinical and laboratory investigators are leading to development of new clinical cancer trials.
|Link, Laura A; Howley, Breege V; Hussey, George S et al. (2016) PCBP1/HNRNP E1 Protects Chromosomal Integrity by Translational Regulation of CDC27. Mol Cancer Res 14:634-46|
|Nelson, Michelle H; Bowers, Jacob S; Bailey, Stefanie R et al. (2016) Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning. J Immunother Cancer 4:6|
|Podbielska, Maria; Szulc, ZdzisÅ‚aw M; Kurowska, Ewa et al. (2016) Cytokine-induced release of ceramide-enriched exosomes as a mediator of cell death signaling in an oligodendroglioma cell line. J Lipid Res 57:2028-2039|
|Sambandam, Yuvaraj; Sakamuri, Sashank; Balasubramanian, Sundaravadivel et al. (2016) RANK Ligand Modulation of Autophagy in Oral Squamous Cell Carcinoma Tumor Cells. J Cell Biochem 117:118-25|
|Miller, Kayla; Dixit, Suraj; Bredlau, Amy-Lee et al. (2016) Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers. Nanomedicine (Lond) 11:581-95|
|Basher, Fahmin; Jeng, Emily K; Wong, Hing et al. (2016) Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC. Oncotarget 7:814-30|
|Small, James; Flanagan, Catherine; Armeson, Kent et al. (2016) Family history of cutaneous and noncutaneous malignancies in relation to the risk of keratinocyte carcinoma coupled with another type of cancer: A case-control study. J Am Acad Dermatol 75:1066-1068.e7|
|Maldonado, Eduardo N; DeHart, David N; Patnaik, Jyoti et al. (2016) ATP/ADP Turnover and Import of Glycolytic ATP into Mitochondria in Cancer Cells Is Independent of the Adenine Nucleotide Translocator. J Biol Chem 291:19642-50|
|Hendriks, Giel; Derr, Remco S; Misovic, Branislav et al. (2016) The Extended ToxTracker Assay Discriminates Between Induction of DNA Damage, Oxidative Stress, and Protein Misfolding. Toxicol Sci 150:190-203|
|Paul, Matt R; Levitt, Nicholas P; Moore, David E et al. (2016) Multivariate models from RNA-Seq SNVs yield candidate molecular targets for biomarker discovery: SNV-DA. BMC Genomics 17:263|
Showing the most recent 10 out of 311 publications